Regencell Bioscience's 15min chart shows expanding Bollinger Bands and bullish Marubozu.

Regencell Bioscience's 15-minute chart has exhibited a bullish trend, with Bollinger Bands expanding upward and a bullish Marubozu candlestick pattern observed on October 3, 2023 at 10:45. This suggests that buyers are in control of the market, and the bullish momentum is expected to persist.

Regencell Bioscience Holdings Limited (NASDAQ: RGC), a Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders such as ADHD and autism spectrum disorder (ASD), has shown a bullish trend in its 15-minute chart. As of October 3, 2023, at 10:45, the company's chart exhibited an upward expansion of Bollinger Bands and a bullish Marubozu candlestick pattern. This suggests that buyers are in control of the market, and the bullish momentum is expected to persist Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results^[1].

On September 21, 2025, RGC was added to the S&P Global BMI Index, which may enhance its liquidity and help stabilize the stock, which has been highly volatile. Despite this progress, the business continues to face fundamental challenges, including zero revenue, ongoing losses, and uncertain regulatory pathways for its treatments. The company reported positive results from its second efficacy trial using standardized TCM formulae for ADHD and ASD, showing a mean symptom improvement of 37% with no adverse side effects. However, no FDA-approved products have been announced yet, and the treatments remain investigational Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results^[1].

Regencell Bioscience's stock experienced extreme volatility in mid-2025, peaking with an approximate 14,899% year-to-date gain by June, driven by speculative trading, a stock split, and excitement over trial results. Following this peak, shares saw sharp intra-day swings and a pullback. Technical indicators in September suggest a potential upward trend, supported by positive momentum and movement above its 50-day moving average.

While we acknowledge the potential of RGC as an investment, certain AI stocks may offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results^[1].